So You Think You’re Done? The Real Deal on Continuing Review
You’ve crossed the finish line. The champagne’s been popped (or at least, the cheap sparkling cider). And the IRB signed off. Your study got approved. Time to breathe, right?
Not so fast Most people skip this — try not to..
If you’re running a study that lasts more than a few months—especially anything involving human subjects—there’s a quiet, ongoing responsibility that doesn’t end with that initial approval letter. It’s called continuing review, and it’s the part most researchers, especially those new to the game, tend to underestimate, forget, or straight-up dread.
But here’s the thing: it’s not just a bureaucratic hoop. In real terms, it’s the backbone of ethical, compliant, and actually-successful research. Skip it, and you’re not just risking a slap on the wrist from your IRB. You’re risking participant safety, data integrity, and the validity of everything you’ve worked for.
So what is this quiet watchdog, and why does it matter so much? Let’s pull back the curtain Simple, but easy to overlook..
What Is Continuing Review, Really?
At its core, continuing review is the periodic re-evaluation of an ongoing study by an Institutional Review Board (IRB) or Ethics Committee. It’s not a one-and-done deal. So s. But once your initial protocol is greenlit, most jurisdictions—including the U. Common Rule—require that the study be reviewed at least annually, and sometimes more frequently depending on the level of risk involved It's one of those things that adds up. No workaround needed..
Think of it like this: your initial approval was the IRB saying, “Based on what you’ve told us, this plan looks okay to start.” Continuing review is them checking in to say, “Alright, how’s it actually going? Are participants still safe? Are you sticking to the plan? Have any new risks popped up?
It’s a formal process, usually involving a submission packet—updated consent forms, progress reports, summaries of any adverse events, and sometimes a full or expedited review. The goal isn’t to micromanage, but to make sure the study remains ethical and compliant throughout its entire lifespan, from first recruitment to final data lock.
The Legal and Ethical Backbone
The requirement isn’t arbitrary. It stems from some hard-learned lessons in research history. Because of that, studies that looked good on paper sometimes veered off course in practice. Worth adding: participant protections can erode over time. New information can emerge that changes the risk-benefit calculus. Continuing review is the system’s way of building in a safeguard against those slow, creeping failures Most people skip this — try not to..
Why Bother? The Stakes of Skipping Out
Why does this matter so much? Can’t you just… keep working and submit everything when the study ends?
No. And here’s why that’s a dangerous game.
First, and most importantly, it’s about the people who volunteered for your study. They trusted you with their time, their data, sometimes their health. Continuing review ensures that if a new risk emerges—say, an unexpected side effect in a clinical trial, or a data breach in a social science study—you catch it, report it, and adjust. It’s an active duty of care Easy to understand, harder to ignore..
Second, it’s about your data’s credibility. On the flip side, you might have to tell them to pause. Your publication record? On the flip side, that means you have to stop enrolling new participants, and often, you have to freeze data collection. All that momentum? So gone. That's why all those participants you’ve been following? Which means if your IRB finds out you’ve let your approval lapse, they can suspend your study. Potentially tainted if the study is deemed non-compliant.
Third, it’s about funding and future work. Federal grants, university policies, and journal submission guidelines all require proof of IRB compliance. A lapsed approval can jeopardize current funding and sink future applications. It signals poor stewardship.
And finally, it’s the law. And it’s a regulatory requirement. For studies funded by the U.Department of Health and Human Services, the FDA, or most major public funders, continuing review isn’t optional. But s. Getting caught out can lead to audits, reporting to federal agencies, and serious institutional penalties.
How Continuing Review Actually Works (The Step-by-Step)
So you know you have to do it. But what does “doing it” actually entail? The process is more straightforward than people fear, but it demands organization and foresight.
1. Know Your Schedule and Deadlines
Basically the most critical step, and the one most people mess up. Your IRB will give you an approval period—usually one year, sometimes less for higher-risk studies. Mark that expiration date in your calendar. Here's the thing — not just once. On the flip side, set multiple reminders—six months out, three months out, one month out. Why? Still, because the review process itself can take time. Because of that, if your approval expires on October 1st, you need to submit your continuing review packet well before that, often 30-60 days prior, to allow for review and a new approval letter to be issued before the old one runs out. A lapsed approval is a gap in oversight, and that’s a big no-no.
Real talk — this step gets skipped all the time.
2. Gather Your Updated Materials
What you submit depends on your study and your IRB’s requirements, but a standard packet usually includes:
- A progress report: How many participants have been enrolled? How many have completed? What data have you collected? Are you on track with your timeline?
- Summary of adverse events: This is huge. You must report all serious and unexpected adverse events, and summarize any other problems. Even if nothing major happened, you report “none.”
- Changes since last review: Did you amend the protocol? Change a consent form? Switch data collection platforms? You must disclose everything.
- Status of ongoing consent: Are you still using the approved consent documents? Have there been any issues with participant understanding?
- Any new relevant information: This could be new literature that affects the risk profile, changes in regulations, or security breaches.
3. Choose the Review Type
Your IRB will determine if your study qualifies for an expedited review (for minimal risk studies) or requires a full board meeting. Most studies in good standing with no major changes cruise through an expedited renewal. But if there have been significant new risks or protocol deviations, it might go to a full board. The key is transparency—lay it all out, and let the IRB decide No workaround needed..
4. Await the Decision and Implement
If the IRB approves, you’ll get a new approval letter with a new expiration date. Here's the thing — your job is to post that letter, update your study files, and keep moving. If they have questions or require modifications, address them promptly. If they disapprove or suspend, you must stop the study immediately and work with the IRB to fix the issues.
This is the bit that actually matters in practice.
The Landmines: What Most Researchers Get Wrong
This is where theory meets the messy reality of lab benches and field sites. Here are the most common—and costly—mistakes.
Treating It as a Formality
The biggest error? Seeing continuing review as just another form to fill out. It’s not The details matter here..
Treating It as a Formality
The biggest error? Seeing continuing review as just another form to fill out. That's why it’s not. It’s a moment to critically assess whether your study remains ethical, safe, and scientifically valid. Researchers often rush through the process, copying last year’s progress report or glossing over minor protocol tweaks. Now, this complacency can lead to overlooked risks, outdated consent processes, or unaddressed safety concerns. IRBs are not rubber-stamping machines—they’re watchdogs. Treat the review as a checkpoint to ensure your study hasn’t veered off course.
Underreporting Adverse Events
Another common pitfall is downplaying or omitting adverse events. To give you an idea, a participant dropping out due to discomfort with a procedure might indicate a need to revise the protocol. Similarly, data breaches or technical failures in data collection systems must be disclosed. IRBs need the full picture to protect participants and maintain public trust. Even if an event seems minor, it could signal a larger pattern. Omitting details because they’re “not that bad” can erode credibility and delay approvals Turns out it matters..
And yeah — that's actually more nuanced than it sounds Easy to understand, harder to ignore..
Ignoring Evolving Regulatory Requirements
Regulations change, and IRBs often update their templates or expectations accordingly. A researcher who sticks rigidly to an old format might find their submission bounced back for non-compliance. Even so, stay informed about updates to the Common Rule, GDPR (if applicable), or institutional policies. If your institution adopts a new data management system or consent process, ensure your study aligns with these changes. Failure to adapt can result in unnecessary delays or even study suspension.
Overlooking Participant Feedback
Participants are your best source of real-world insights. So if they express confusion about consent forms, discomfort with procedures, or suggest improvements, document these interactions. Even so, continuing review is an opportunity to address such feedback—perhaps revising consent language for clarity or adjusting recruitment strategies. Ignoring participant perspectives can lead to ethical blind spots and reduced study quality Simple as that..
Procrastination and Last-Minute Submissions
Waiting until the last minute to prepare materials is a recipe for stress and errors. Rushing through the process increases the likelihood of missing critical updates or submitting incomplete information. IRBs often have strict deadlines, and late submissions can result in automatic study closure. Start gathering materials early, ideally 90 days before the expiration date, to allow time for revisions and unforeseen issues Not complicated — just consistent..
Conclusion: Staying Ahead of the Curve
Continuing review isn’t just a bureaucratic hurdle—it’s a cornerstone of ethical research. In practice, by treating it as an opportunity to refine your study, communicate transparently with your IRB, and prioritize participant safety, you safeguard both your research integrity and public trust. Also, set those reminders, gather your materials thoughtfully, and approach each review with the same rigor you applied at the study’s outset. After all, the goal isn’t just to comply with regulations—it’s to ensure your work continues to uphold the highest standards of science and ethics.
Not obvious, but once you see it — you'll see it everywhere.
